Renfeng Guo
Oprichter bij INFLARX N.V.
Vermogen: 2 M $ op 30-04-2024
Actieve functies van Renfeng Guo
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| INFLARX N.V. | Directeur/Bestuurslid | 01-12-2007 | - |
| Hoofd Techniek/Wetenschap/O&O | 01-12-2007 | - | |
| Oprichter | 01-12-2007 | - |
Loopbaan van Renfeng Guo
Eerdere bekende functies van Renfeng Guo
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| University of Michigan | Corporate Officer/Principal | 01-01-2001 | - |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Directeur/Bestuurslid | - | - |
| Hoofd Techniek/Wetenschap/O&O | 11-12-2007 | - | |
| Oprichter | 25-11-2009 | - |
Opleiding van Renfeng Guo
| Norman Bethune Medical University | Doctorate Degree |
Statistieken
Internationaal
| Duitsland | 3 |
| China | 2 |
| Verenigde Staten | 2 |
Operationeel
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INFLARX N.V. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
- Beurs
- Insiders
- Renfeng Guo
- Ervaring
